Impact of OAS1 Exon 7 rs10774671 Genetic Variation on Liver Fibrosis Progression in Egyptian HCV Genotype 4 Patients

Viral Immunology

Volumn 28, Issue 9, 2015, Pages 509-516

  Bader El Din, Noha G ^a   Anany, Mohamed A ^a   Dawood, Reham M ^a   Ibrahim, Marwa K ^a   El Shenawy, Reem ^a   El Abd, Yasmin S ^a   El Awady, Mostafa K ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EGYPTIAN; EXON; FEMALE; GENE; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OLIGOADENYLATE SYNTHETASE 1 GENE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS; AGED; CHRONIC HEPATITIS C; CLASSIFICATION; COMPLICATION; EGYPT; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; MIDDLE AGED; PROGNOSIS; VIROLOGY;

2',5' OLIGOADENYLATE SYNTHETASE; OAS1 PROTEIN, HUMAN;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; AGED; ALLELES; DISEASE PROGRESSION; EGYPT; EXONS; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84946198467     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2015.0041     Document Type: Article

References (37)

1. Bader el-Din NG, Abd el-Meguid M, Tabll AA, et al. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol 2011;26:55-62.
2. Bader El Din NG, Salum GM, Anany M, et al. Association of myxovirus resistance gene promoter polymorphism with response to combined interferon treatment and progression of liver disease in chronic HCV Egyptian patients. J Interferon Cytokine Res 2015;35:641-648.
3. Bedossa P, and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
4. Bigham AW, Buckingham KJ, Husain S, et al. Host genetic risk factors for West Nile Virus infection and disease progression. PLoS One 2012;6:e2475.
5. Bonnevie-Nielsen V, Field LL, Lu S, et al. Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005;76:623-633.
6. Chen S, and Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.
7. El Awady MK, Anany MA, Esmat G, et al. Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol 2011;26:843-850.
8. El Awady MK, Bader El Din NG, Tabll A, et al. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol 2013;19:290-298.
9. El-Awady MK, el-Din NG, el-Garf WT, et al. Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. Cancer Cell Int 2006;6:18.
10. El-Awady MK, Ismail SM, El-Sagheer M, et al. Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCV-associated hepatitis. Clin Chim Acta 1999;283:1-14.
11. El-Awady MK, Mostafa L, Tabll AA, et al. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon 2012;12:271-277.
12. Fedetz M, Matesanz F, Caro-Maldonado A, et al. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 2006;68:446-449.
13. Ghosh A, Sarkar SN, Rowe TM, et al. A specific isozyme of 2′-5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001;276:25447-25455.
14. Hajarizadeh B, Grebely J, and Dore G. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-562.
15. Hamano E, Hijikata M, Itoyama S, et al. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun 2005;329:1234-1239.
16. Hold GL, Untiveros P, Saunders KA, et al. Role of host genetics in fibrosis. Fibrogenesis Tissue Repair 2009;2:6.
17. Imran M, Manzoor S, Ashraf J, et al. Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J 2013;10:299-311.
18. Imran M, Manzoor S, Khattak NM, et al. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan. Viral Immunol 2014;27:105-111.
19. Karoney M, and Siika A. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J 2013;14:44-49.
20. Kjær K, Pahus J, Hansen M, et al. Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide polymorphism. BMC Cell Biol 2014;15:33-47.
21. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003;4:411-419.
22. Larrubia JR, Benito-Martínez SM, Calvino E, et al. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008;14:7149-7159.
23. Lauer GM, and Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
24. Li CZ, Kato N, Chang JH, et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int 2009;29:1413-1421.
25. Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile Virus in man. PLoS Pathog 2009;5:e1000321.
26. Lin RJ, Yu HP, Chang BL, et al. Distinct antiviral roles for human 2′,5′-oligoadenylate synthetase family members against dengue virus infection. J Immunol 2009;183:8035-8043.
27. Mashimo T, Glaser P, Lucas M, et al. Structural and functional genomics and evolutionary relationships in the cluster of genes encoding murine 2′,5′-oligoadenylate synthetases. Genomics 2003;82:537-552.
28. Mitra A, Satelli A, Yan J, et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 2014;60:2027-2039.
29. Mohamoud YA, Mumtaz GR, Riome S, et al. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013;13:288-309.
30. Noguchi S, Hamano E, Matsushita I, et al. Differential effects of a common splice site polymorphism on the generation of OAS1 variants in human bronchial epithelial cells. Hum Immunol 2013;74:395-401.
31. Pasha HF, Radwan MI, Hagrass HA, et al. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine 2013;61:478-484.
32. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-1345.
33. Sato M, Kondo M, Tateishi R, et al. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 2014;9:e91822.
34. Tessier MC, Qu HQ, Frechette R, et al. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? J Med Genet 2006;43:129-132.
35. Torres M, and Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003;2:5-11.
36. Wang H, Mengsteab S, Tag CG, et al. Transforming growth factor beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005;11:1929-1936.
37. Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.